W M Linehan

List of Publications by Year
in descending order

104 papers	23,029 citations	13865 67 h-index	32842 100 g-index
106 all docs	106 docs citations	106 times ranked	12154 citing authors

#	Article	IF	Citations
1	International cancer seminars: a focus on kidney cancer. Annals of Oncology, 2016, 27, 1382-1385.	1.2	18
2	Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma. Urology Case Reports, 2014, 2, 39-42.	0.3	1
3	Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Research, 2012, 22, 2089-2100.	5.5	202
4	Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution. Hormone and Metabolic Research, 2012, 44, 343-348.	1.5	11
5	Inactivation of the von Hippelâ€“Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene, 2011, 30, 4697-4706.	5.9	59
6	Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine-Related Cancer, 2010, 18, 97-111.	3.1	169
7	Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727.	7.1	203
8	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154.	6.3	223
9	BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. Journal of Medical Genetics, 2008, 45, 321-331.	3.2	420
10	HIF and fumarate hydratase in renal cancer. British Journal of Cancer, 2007, 96, 403-407.	6.4	54
11	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557.	7.1	427
12	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	3.8	24
13	Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. Journal of Medical Genetics, 2006, 43, 755-762.	3.2	49
14	Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. Journal of Medical Genetics, 2005, 43, 18-27.	3.2	261
15	Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6958-6963.	7.1	165
16	Comorbid VHL and SCA2 mutations in a large kindred: confounding diagnosis of neurological dysfunction caused by CNS VHL vascular tumours versus SCA2 atrophic neurodegeneration. Journal of Medical Genetics, 2002, 39, 37e-37.	3.2	0
17	Comorbid genetic diseases, von Hippel-Lindau disease and spinocerebellar ataxia type 2, confounding the diagnosis of cerebellar dysfunction in an adolescent. Clinical Neurology and Neurosurgery, 2001, 103, 216-219.	1.4	3
18	Birt-Hogg-DubÃ© Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. American Journal of Human Genetics, 2001, 69, 876-882.	6.2	355

#	Article	IF	Citations
19	INTRAOPERATIVE ULTRASOUND DURING RENAL PARENCHYMAL SPARING SURGERY FOR HEREDITARY RENAL CANCERS:: A 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 397-400.	0.4	54
20	The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Current Opinion in Urology, 2001, 11, 463-469.	1.8	33
21	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	3.9	512
22	Partial adrenalectomy in patients with multiple adrenal tumors. Current Urology Reports, 2001, 2, 19-23.	2.2	12
23	Molecular Analysis of the von Hippel-Lindau Disease Gene. Methods in Molecular Medicine, 2001, 53, 193-216.	0.8	1
24	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	3.6	262
25	Prostate Cancer: Where are We Going?. Baylor University Medical Center Proceedings, 2000, 13, 366-367.	0.5	0
26	Molecular Genetics of Kidney Cancer: Implications for the Physician. Baylor University Medical Center Proceedings, 2000, 13, 368-371.	0.5	1
27	Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients. American Journal of Pathology, 2000, 157, 1615-1621.	3.8	136
28	Molecular Profiling of Clinical Tissue Specimens. American Journal of Pathology, 2000, 156, 1109-1115.	3.8	84
29	Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery, 2000, 128, 1022-1028.	1.9	98
30	Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation. New England Journal of Medicine, 2000, 343, 750-758.	27.0	977
31	Molecular Profiling of Clinical Tissue Specimens. Journal of Molecular Diagnostics, 2000, 2, 60-66.	2.8	54
32	Mosaicism in von Hippelâ€“Lindau Disease: Lessons from Kindreds with Germline Mutations Identified in Offspring with Mosaic Parents. American Journal of Human Genetics, 2000, 66, 84-91.	6.2	165
33	Hereditary Papillary Renal Carcinoma: Pathology and Pathogenesis. , 1999, 128, 11-27.		6
34	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippelâ€“Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	27.0	335
35	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487
36	Pheochromocytoma: evaluation, diagnosis, and treatment. World Journal of Urology, 1999, 17, 35-39.	2.2	133

#	Article	IF	Citations
37	INTRINSIC DRUG RESISTANCE IN PRIMARY AND METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1999, 162, 217-224.	0.4	23
38	INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. Journal of Urology, 1999, 162, 43-45.	0.4	102
39	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.4	233
40	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.4	229
41	Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. American Journal of Pathology, 1999, 155, 517-526.	3.8	243
42	VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma. JAMA Ophthalmology, 1999, 117, 625.	2.4	133
43	The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells. Molecular and Cellular Biology, 1999, 19, 5902-5912.	2.3	194
44	Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 1998, 20, 66-69.	21.4	291
45	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	2.5	452
46	Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations. Surgery, 1998, 124, 1153-1159.	1.9	197
47	Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. American Journal of Pathology, 1998, 153, 223-231.	3.8	243
48	FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. Journal of Urology, 1998, 160, 335-340.	0.4	127
49	Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer. Journal of the National Cancer Institute, 1998, 90, 233-237.	6.3	191
50	Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Research, 1998, 58, 1719-22.	0.9	146
51	Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9102-9107.	7.1	319
52	The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family ofâ€‰proteins. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2156-2161.	7.1	464
53	CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1997, 158, 1675-1678.	0.4	120
54	Laparoscopic adrenalectomy: A new standard of care. Urology, 1997, 49, 673-678.	1.0	176

#	Article	IF	Citations
55	Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. Urology, 1997, 50, 302-307.	1.0	47
56	Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma. Human Pathology, 1997, 28, 411-415.	2.0	54
57	von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Human Pathology, 1997, 28, 540-543.	2.0	176
58	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	5.9	298
59	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	21.4	1,461
60	Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA - Journal of the American Medical Association, 1997, 277, 1461-1466.	7.4	204
61	Imaging Features of Hereditary Papillary Renal Cancers. Journal of Computer Assisted Tomography, 1997, 21, 737-741.	0.9	63
62	Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. American Journal of Pathology, 1997, 151, 951-6.	3.8	67
63	Von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Human Pathology, 1996, 27, 152-156.	2.0	41
64	Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenetic and Genome Research, 1996, 75, 17-21.	1.1	44
65	Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10589-10594.	7.1	497
66	Interaction of von Hippel-Lindau tumor suppressor gene product with elongin. Methods in Enzymology, 1996, 274, 436-441.	1.0	7
67	Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1770-1775.	7.1	137
68	Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1242, 201-210.	7.4	77
69	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World Journal of Urology, 1996, 14, S2-7.	2.2	10
70	The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Human Molecular Genetics, 1996, 5, 1333-1338.	2.9	245
71	Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation.. Radiology, 1996, 198, 785-788.	7.3	286
72	Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. Cancer Treatment and Research, 1996, 88, 13-39.	0.5	12

#	Article	IF	Citations
73	Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. American Journal of Pathology, 1996, 149, 2089-94.	3.8	126
74	Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Research, 1996, 56, 2411-6.	0.9	187
75	Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6459-6463.	7.1	144
76	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156.	2.8	48
77	von Hippel-Lindau disease: genetic, clinical, and imaging features.. Radiology, 1995, 194, 629-642.	7.3	494
78	Inhibition of transcription elongation by the VHL tumor suppressor protein. Science, 1995, 269, 1402-1406.	12.6	557
79	Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA - Journal of the American Medical Association, 1995, 273, 564-570.	7.4	213
80	A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. American Journal of Pathology, 1995, 146, 620-5.	3.8	198
81	Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. Journal of Urology, 1995, 154, 2010-4; discussion 2014-5.	0.4	50
82	Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Research, 1995, 55, 2959-62.	0.9	230
83	Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA - Journal of the American Medical Association, 1995, 273, 564-70.	7.4	95
84	Hereditary Papillary Renal Cell Carcinoma. Journal of Urology, 1994, 151, 561-566.	0.4	289
85	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9700-9704.	7.1	1,382
86	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. Journal of Surgical Oncology, 1993, 53, 252-255.	1.7	4
87	Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology, 1993, 42, 250-257.	1.0	87
88	Mapping the Von Hippel â€" Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Human Molecular Genetics, 1993, 2, 879-882.	2.9	53
89	The Management of Isolated Renal Recurrence of Renal Cell Carcinoma Following Complete Response to Interleukin-2 Based Immunotherapy. Journal of Urology, 1993, 150, 176-178.	0.4	9
90	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. Journal of Urology, 1993, 150, 463-466.	0.4	132

#	Article	IF	Citations
91	Immunotherapy with Interleukin-2 and Î± -Interferon in Patients with Metastatic Renal Cell Cancer with in Situ Primary Cancers: A Pilot Study. Journal of Urology, 1992, 147, 24-30.	0.4	67
92	Renal cell carcinoma: Resection of solitary and multiple metastases. Annals of Thoracic Surgery, 1992, 54, 33-38.	1.3	99
93	Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay. Endocrinology, 1992, 131, 2263-2270.	2.8	5
94	Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Research, 1992, 52, 348-56.	0.9	79
95	Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Research, 1991, 51, 1071-7.	0.9	127
96	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. Journal of Urology, 1990, 144, 614-617.	0.4	90
97	Collecting duct carcinoma of the kidney. Human Pathology, 1990, 21, 449-456.	2.0	211
98	Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.. Journal of Clinical Oncology, 1989, 7, 1863-1874.	1.6	386
99	Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients. Annals of Surgery, 1989, 210, 474-485.	4.2	917
100	Renal Toxicity of Interleukin-2 Administration in Patients With Metastatic Renal Cell Cancer: Effect of Pre-therapy Nephrectomy. Journal of Urology, 1989, 141, 499-502.	0.4	45
101	Renal Cell Carcinoma. Journal of Urology, 1988, 139, 340-341.	0.4	4
102	This Month in Investigative Urology: Adoptive Immunotherapy of Genitourinary Tumors with Interleukin-2. Journal of Urology, 1988, 140, 838-839.	0.4	0
103	Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.. Journal of Clinical Oncology, 1988, 6, 839-853.	1.6	403
104	A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone. New England Journal of Medicine, 1987, 316, 889-897.	27.0	2,695